Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
“Multiple myeloma is associated with a significant risk of venous thromboembolism (VTE-blood clot), causing substantial levels of morbidity and mortality.”
Thick blood, documented by a high ESR rate is a common multiple myeloma symptom. A deep vein thrombosis, aka aka DVT, aka blood clot, according to research, is a common multiple myeloma side effect of many chemotherapy regimens.
My mantra “If I knew then what I know now” is my way of telling multiple myeloma patients, survivors and caregivers how ignorant I was about MM symptoms and MM side effects when I was first diagnosed.
I developed a blood clot shortly after beginning my induction chemotherapy cocktail of Vincristine, Adriamycin and Dexamethasone.
It never occurred to me that the VAD induction therapy that I had taken two weeks before was the cause of my painful, life threatening deep vein thrombosis. It never occurred to me that the complete trust that I placed in my oncology team was misplaced.
My point above, is that multiple myeloma patients may struggle to manage their incurable blood cancer at the expense of their blood health aka risk of blood clots.
To put this another way, aggressive MM therapy such as chemo, radiation and dexamethasone can manage a patient’s MM while damaging his/her blood health and increase the risk of blood clots at the same time.
A possible solution to the challenge of multiple myeloma symptoms and multiple myeloma side effects that all MM patients face is evidence-based non-conventional therapies such as
The issue discussed in the post are the problems that both MM and MM therapies cause the patient’s blood. I continue to take omega-3 fatty acids, curcumin and resveratrol to manage my MM, my blood, my heart, my brain, my…you get the idea.
“The erythrocyte sedimentation rate (ESR or sed rate) is the rate at which red blood cells in anticoagulated whole blood descend in a standardized tube over a period of one hour. It is a common hematology test, and is a non-specific measure of inflammation…
The ESR is increased in inflammation, pregnancy, anemia, autoimmune disorders (such as rheumatoid arthritis and lupus), infections, some kidney diseases and some cancers (such as lymphoma and multiple myeloma)…
“Myeloma may involve various symptoms, such as kidney failure, bone pain, fatigue from anemia, or headache from plasma hyper-viscosity (increased thickness of the blood).
Of all common cancers, myeloma has the longest interval from initial manifestation of symptoms to diagnosis. A large number of patients are diagnosed only after seeking emergency care, which is linked to to shorter survival…
Although the inflammatory markers C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and plasma viscosity (PV) have been used together to diagnose myeloma, they have not been addressed individually…
“In summary, in this large population-based study based on over 9,000 multiple myeloma patients, we found, in contrast to previously published studies, that the occurrence of any thrombosis was associated with a significantly poorer survival.
Multiple myeloma patients with an early arterial or venous thrombosis had a higher risk of death than patients without.
However, multiple myeloma patients with an early VTE who survived their first six months had similar survival rates to those without VTE. Therefore, our findings confirm that thrombosis in multiple myeloma patients is a serious complication, and that it increases mortality, also in the era of novel agents.”
Multiple myeloma is associated with a significant risk of venous thromboembolism (VTE), causing substantial levels of morbidity and mortality.
The thrombogenicity of myeloma is multifactorial, with disease- and treatment-related factors playing important roles.
in particular, are known to enhance the thrombotic potential of myeloma. For this reason, assessment of the VTE risk has long been advocated prior to treatment initiation in patients with myeloma requiring IMiD-based regimens.
However, despite routine use of thromboprophylaxis, these patients can still develop VTE and its sequelae. The optimum choice and dose of thromboprophylactic drug is not entirely clear, and with this, there is growing interest regarding use of the direct oral anticoagulants in this setting…
We propose an amended risk stratification, and consider management of challenging patients, including those with renal impairment and recurrent thrombosis.”
“Cancer patients have an elevated risk of developing life-threatening blood clots. For some patients, the type of cancer (multiple myeloma) they have can trigger blood clots. Some cancers actually produce substances which can activate the clotting cascade and produce blood clots (thrombosis).
…Additionally, some cancer drug therapies (i.e. Tamoxifen, progestins, aromatase inhibitors, thalidomide, cisplatin, antiangiogenic agents, etc.) and radiation therapy can cause inflammation and injure vascular endothelial walls, a set up for thrombosis.
Platelet activation and aggregation play a central role in hemostasis and thrombosis. Herbal medicines have been traditionally used in the management of cardiovascular disease and can help in modifying its progression, particularly in hemostasis and the coagulation process, as well as altering platelet function tests and some coagulation parameters.
Modern scientific research has demonstrated its anti-inflammatory, antioxidant, anti-carcinogenic, antithrombotic, and cardiovascular protective effects.
The present study reviewed previous studies in the literature, which support the positive activity of curcumin in hemostasis, anticoagulation, and fibrinolysis…”
“This experimental study investigated the prophylactic effects of the antioxidant and antiaggregant compound resveratrol (R) on portal vein thrombosis (PVT) in rats…”